These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 39042352)

  • 1. Correlates of stocking naloxone: a cross-sectional survey of community pharmacists.
    Laing R; Xia T; Grist E; Dostal J; Nielsen S; Picco L
    Int J Clin Pharm; 2024 Dec; 46(6):1362-1370. PubMed ID: 39042352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stocking and supplying naloxone: Findings from a representative sample of community pharmacies in Victoria, Australia.
    Karthikeyan N; Xia T; Nielsen S; Picco L
    Drug Alcohol Rev; 2024 Jul; 43(5):1305-1312. PubMed ID: 38691509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
    Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
    Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.
    Stopka TJ; Donahue A; Hutcheson M; Green TC
    J Am Pharm Assoc (2003); 2017; 57(2S):S34-S44. PubMed ID: 28189540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community pharmacists' attitudes toward and practice of pharmacy-based harm reduction services in Pittsburgh, PA: a descriptive survey.
    O'Brien C; Klipp S; Jawa R; Wilson JD
    Harm Reduct J; 2024 Jul; 21(1):137. PubMed ID: 39030563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
    Thornton JD; Lyvers E; Scott VGG; Dwibedi N
    J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal.
    Nielsen S; Menon N; Larney S; Farrell M; Degenhardt L
    Addiction; 2016 Dec; 111(12):2177-2186. PubMed ID: 27367125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
    Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
    J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
    Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
    Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacists' naloxone services beyond community pharmacy settings: A systematic review.
    Rawal S; Osae SP; Cobran EK; Albert A; Young HN
    Res Social Adm Pharm; 2023 Feb; 19(2):243-265. PubMed ID: 36156267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study.
    Burstein D; Baird J; Bratberg J; Donovan E; Soipe A; Tapper A; Case P; Walley AY; Green TC
    J Am Pharm Assoc (2003); 2020; 60(2):304-310. PubMed ID: 31870862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacy on-site overdose protocols and prevention of overdose.
    Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
    Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
    Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
    Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is known about community pharmacy supply of naloxone? A scoping review.
    Nielsen S; Van Hout MC
    Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
    Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
    Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accessing Take-Home Naloxone in British Columbia and the role of community pharmacies: Results from the analysis of administrative data.
    Moustaqim-Barrette A; Papamihali K; Mamdani Z; Williams S; Buxton JA
    PLoS One; 2020; 15(9):e0238618. PubMed ID: 32915834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing take-home naloxone in an urban community pharmacy.
    Akers JL; Hansen RN; Oftebro RD
    J Am Pharm Assoc (2003); 2017; 57(2S):S161-S167. PubMed ID: 28202384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naloxone rescheduling in Australia: Processes, implementation and challenges with supply of naloxone as a 'pharmacist only' over-the-counter medicine.
    Pricolo A; Nielsen S
    Drug Alcohol Rev; 2018 May; 37(4):450-453. PubMed ID: 28449379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.